Malden, MA, United States of America

Xiaoding Xu

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.1

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
2 patents (USPTO):

Title: The Innovations of Xiaoding Xu

Introduction

Xiaoding Xu is a notable inventor based in Malden, MA (US), recognized for his contributions to medical technology and therapeutic advancements. With a total of two patents to his name, he has made significant strides in addressing liver conditions and developing novel particle systems for drug delivery.

Latest Patents

Xu's latest patents include groundbreaking work on therapeutic targets involved in the progression of nonalcoholic steatohepatitis (NASH). This invention focuses on methods and compositions for specifically modulating the Hippo pathway transcription factor TAZ (WWTR1) as a therapeutic target for inhibiting or preventing liver conditions, including the progression of steatosis-to-NASH in patients. Another significant patent involves amphiphile-polymer particles, which details a process for creating particles that consist of a water-insoluble polymeric core, a payload, and an amphiphile, aimed at enhancing drug delivery systems.

Career Highlights

Throughout his career, Xu has worked with prestigious institutions such as Brigham and Women's Hospital and Harvard College. His work in these environments has allowed him to collaborate with leading experts in the field and contribute to innovative research.

Collaborations

Some of his notable coworkers include Omid C Farokhzad and Jinjun Shi, who have also made significant contributions to the fields of medicine and technology.

Conclusion

Xiaoding Xu's innovative patents and career achievements highlight his dedication to advancing medical technology and improving patient outcomes. His work continues to influence the field and pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…